Pretax income is the income that a company earns before paying income taxes. Protalix BioTherapeutics's pretax income for the
three
months ended in Dec. 2023 was $-6.43 Mil.
Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $8.57 Mil.
Protalix BioTherapeutics's pretax margin was -61.28%.
During the past 13 years, Protalix BioTherapeutics's highest Pretax Margin was 13.08%. The lowest was -945.16%. And the median was -74.60%.
Protalix BioTherapeutics Pre-Tax Income Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Protalix BioTherapeutics's Pre-Tax Income
For the Biotechnology subindustry, Protalix BioTherapeutics's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Protalix BioTherapeutics's Pre-Tax Income Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Protalix BioTherapeutics's Pre-Tax Income distribution charts can be found below:
* The bar in red indicates where Protalix BioTherapeutics's Pre-Tax Income falls into.
Protalix BioTherapeutics Pre-Tax Income Calculation
This is the income that a company earns before paying income taxes.
Protalix BioTherapeutics's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as
Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.57 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics (AMEX:PLX) Pre-Tax Income Explanation
Protalix BioTherapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as
During the past 13 years, Protalix BioTherapeutics's highest Pretax Margin was 13.08%. The lowest was -945.16%. And the median was -74.60%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Protalix BioTherapeutics Pre-Tax Income Related Terms
Thank you for viewing the detailed overview of Protalix BioTherapeutics's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.
Protalix BioTherapeutics (Protalix BioTherapeutics) Business Description
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
PLX has been successfully added to your 